Healthcare Review: Omeros, Eli Lilly, ISIS Pharmaceuticals, Illumina, Gentiva Health Services Print E-mail
By Staff and Wire Reports   
Thursday, 19 September 2013 13:19
U.S. stocks opened slightly higher on Thursday, with the S&P 500 hitting a new intraday record high, a day after the Federal Reserve surprised markets by keeping its stimulus measures intact. The Dow Jones industrial average rose 14.1 points, or 0.09 percent, to 15,691.04, the S&P 500 gained 4.25 points, or 0.25 percent, to 1,729.77 and the Nasdaq Composite added 14.4 points, or 0.38 percent, to 3,798.088.

Omeros ($OMER) is still riding high from Monday's Wedbush OMS302 call — initiates enrollment in a Phase 2 trial of the PDE10 inhibitor OMS824 in patients with stable schizophrenia. The trial will "evaluate ... tolerability, safety, pharmacokinetics, [and] potential interactions with concomitant antipsychotic medications. "Findings will help determine "appropriate dosing regimens and endpoints" for planned Phase 2 and 3 studies.

Eli Lilly ($LLY) inks a collaboration deal with molecular diagnostic test maker Exosome Diagnostics for "biomarker discovery and validation" using Exosome's EXO50 nucleic acid extraction kit. The idea is for LLY to get a head start on the identification of gene mutations that might be connected to "drug response and disease recurrence. "Financial terms weren't disclosed.

ISIS Pharmaceuticals ($ISIS) is out with some additional data from a Phase 1 study of the antisense drug ISIS-SMNRx in spinal muscular atrophy. The follow-up prelim data show "most children" that got the 6 and 9 mg doses continued to demonstrate improvement in tests of muscle function at up to 14 months. HFMSE score improvement was dose dependent, with the 9 mg cohort doing the best and no children exhibiting declining scores.

Illumina's ($ILMN) Verinata Health publishes peer-reviewed verifi data which the company says "validates [its] approach to non-invasive prenatal testing.” The data show verifi correctly detected aneuploidies (that's a chromosome abnormality) "across all test samples." Verinata says this shows testing "based on deeper sequencing delivers highly accurate results regardless of the variation in fetal fraction."

Gentiva Health Services ($GTIV) will acquire Harden Healthcare's home health, hospice, and community care businesses for ~$408.8M ($355M in cash and $53.8M in stock).The cash portion will be funded by "available cash and a new $855M term loan facility" which the company is raising to complete the deal and refinance existing term loans. After the purchase, GTIV's revenue will be 49% home health, 41% hospice, and 10% community care.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter